Mylan Inc (MYL)

Industry: Drugs

Price: $22.98

Chaikin Power Gauge Report | Generated: Mon Mar 26 12:22 EDT 2012 Power Gauge Rating

MYL - Bullish
The Chaikin Power Gauge Rating for MYL is bullish due to very strong earnings performance and bullish price/volume activity. The rating also reflects negative expert opinions. MYL's earnings performance is very strong as a result of an upward trend in earnings this year and a relatively low projected P/E ratio.
TM

News Sentiment Rating

Bullish
MYL Mylan Inc March 21, 2012

Chaikin Sentiment Gauge for MYL is bullish. There is currently a significant positive sentiment within news stories concerning MYL.

TM

News Sentiment :Positive

Power Trend - 5 Year Chart

The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.

High Potential

Neutral

Low Potential

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

www.chaikinpowertools.com

Financials & Earnings

Financial Metrics

Financial Metrics Rating

LT Debt/Equity Ratio

Neutral
MYL's financial metrics are neutral. The company has high revenue per share and is carrying too much long term debt relative to its industry group. The rank is based on a high long term debt to equity ratio relative to its industry group, high price to book value ratio, high return on equity, low price to sales ratio and relatively low cash flow.

Price to Book Value

Return on Equity

Price to Sales Ratio

Business Value

Assets and Liabilities

Ratio Current Ratio LT Debt/Equity TTM 1.39 1.38

Valuation
Ratio Price/Book Price/Sales TTM 2.80 1.60

Returns
Ratio Return on Invest Return on Equity TTM 10.6% 24.2%

Earnings Performance

Earnings Performance Rating

Earnings Growth

Very Bullish
MYL's earnings performance has been very strong. The company experienced superior earnings growth in the past 12 months and is priced relatively low compared to next year's projected EPS. The rank is based on an upward trend in earnings this year, a relatively low projected P/E ratio and consistent earnings over the past 5 years.

Earnings Surprise

Earnings Trend

Projected P/E Ratio

Earnings Consistency

5 Year Revenue and Earnings Growth

12/07 Revenue(M) Rev % Growth EPS EPS % Growth 2,666.02 65.40% $-4.91 -586.14% 12/08 5,137.58 92.71% $-1.05 78.62% 12/09 5,092.78 -0.87% $0.31 129.52% 12/10 5,450.52 7.02% $0.69 122.58% 12/11 6,129.82 12.46% $1.25 81.16%

EPS Estimates
Factor Quarterly EPS Yearly EPS Factor 3-5 year EPS Actual EPS Prev $0.24 $1.25 Actual EPS Growth 35.35% EST EPS Current $0.52 $2.44 Est EPS Growth 9.51% Change +0.28 +1.19 Change -25.84

EPS Surprise
Estimate Latest Qtr 1 Qtr Ago 2 Qtr Ago 3 Qtr Ago $0.50 $0.51 $0.45 $0.44 Actual $0.53 $0.55 $0.52 $0.44 Difference $0.03 $0.04 $0.07 $0.00 % Difference 6.00 7.84 15.56 0.00

EPS Quarterly Results

FY 12/09 12/10 12/11 Qtr 1 $0.23 $0.20 $0.24 Qtr 2 $0.19 $0.17 $0.34 Qtr 3 $-0.13 $0.35 $0.37 Qtr 4 $0.01 $0.01 $0.30 Total $0.30 $0.73 $1.25

Fiscal Year End Month is December.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

www.chaikinpowertools.com

Price Trend & Expert Opinions

Price/Volume Activity

Price/Volume Activity Rating

Relative Strength vs Market

Bullish
Price and volume activity for MYL is bullish. MYL is experiencing sustained buying and has outperformed the S&P 500 over 26 weeks. The rank for MYL is based on positive Chaikin money flow.

Chaikin Money Flow

Price Trend

Price Trend ROC

Volume Trend

Relative Strength vs S&P500 Index

Chaikin Money Flow

Chart shows whether MYL is performing better or worse than the market.

Chaikin Money Flow analyzes supply and demand for a company's stock.

Price Activity
Factor 52 Week High 52 Week Low % Change YTD Rel S&P 500 Value 25.23 16.16 -4.47%

Price Activity
Factor % Change Price - 4 Weeks % Change Price - 24 Weeks % Change Price - 4 Wks Rel to S&P % Change Price - 24 Wks Rel to S&P Value -3.00% 31.01% -5.33% 9.25%

Volume Activity
Factor Average Volume 20 Days Average Volume 90 Days Chaikin Money Flow Persistency Value 5,238,400 5,543,251 69%

Expert Opinions

Expert Opinions

Earnings Estimate Revisions

Bearish
Expert opinions about MYL are negative. Analysts's opinions on MYL have been more negative recently and short interest in MYL is high. The rank for MYL is based on analysts revising earnings estimates upward, a high short interest ratio, insiders purchasing stock, pessimistic analyst opinions and relative weakness of the stock versus the Drugs industry group.

Short Interest

Insider Activity

Analyst Opinions

Relative Strength vs Industry

Earnings Estimate Revisions

Current Current Qtr Next Qtr 0.52 0.58 Current Current FY 2.44 7 Days Ago % Change 0.52 0.58 0.00% 0.00%

Analyst Recommendations
Factor Mean this Week Mean Last Week Change Mean 5 Weeks Ago Value Buy Buy 0.00 Buy

EPS Estimates Revision Summary

Last Week Up Curr Qtr Curr Yr Next Qtr 0 0 1 0 Down 1 0 0 0 Last 4 Weeks Up 0 1 1 2 Down 3 0 2 0

30 Days Ago % Change 2.43 0.01

Next Yr

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

www.chaikinpowertools.com

The Company & Its Competitors

MYL's Competitors in Drugs

Company MYL IPXL WPI TEVA PRX RDY SCR HITK Power Gauge Historic EPS growth 35.35% 50.69% 18.82% 16.94% 12.80% 38.12% 14.96% 24.65% Projected EPS growth 9.51% 15.61% 8.68% 8.40% 7.76% 25.00% 5.17% Profit Margin 8.76% 12.77% 5.69% 15.07% -2.82% 15.63% 8.74% 22.59% PEG 0.99 0.86 1.31 0.92 1.35 0.70 3.94 PE 11.26 24.09 13.70 8.65 11.20 19.28 21.51 9.20 Revenue(M) 6,130 513 4,584 18,312 926 1,677 324 191

News Headlines for MYL BRIEF: Mylan receives approval for generic Boniva - Mar 21, 2012 Mylan One of First to Launch Generic Version of Boniva - Mar 20, 2012 Mylan Canada Receives Health Canada Approval for Generic Version of Crestor - Mar 15, 2012 Mylan Launches First Equivalent Product to Lexapro Tablets - Feb 29, 2012 Mylan Receives Tentative FDA Approval Through PEPFAR for Pediatric HIV/AIDS Therapy - Feb 23, 2012

Company Details Mylan Inc 1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PA 15317 USA Phone: 724-514-1800 Fax: 724-514-1870 Website: http://http://www.mylan.com Full Time Employees: 18,000 Sector: Medical

Company Profile Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.

LM 2.3 DS 3.0 LS 2.1

Data Provided by ZACKS Investment Research, Inc., www.zacks.com

Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com